Adverum Biotechnologies Inc

ADVM

NASDAQ. Currency in USD

0.62 0.00 ( 0.00% )

Real time prices: December 09

Market Cap.
61.83M
Beta (5Y monthly)
1.03
Price/Earnings
-
EPS (TTM)
-1.57
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
265,832
1y Target Est.
3.67
Day's Range
0.62
-
0.64
52 Week's Range
0.61
-
2.04

Historical Summary

Performance
EPS growth
Share Buybacks

About Adverum Biotechnologies Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.adverum.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
98.15M
Employees
188
Address
800 Saginaw Drive, Redwood City, CA, United States, 94063
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Latest news

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...
By GlobeNewswire Inc. - 3 days ago

Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT)...
By GlobeNewswire Inc. - 5 weeks ago

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...
By GlobeNewswire Inc. - 6 weeks ago

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now? Hot...
By PennyStocks - 10 weeks ago

Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD

- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable...
By GlobeNewswire Inc. - 10 weeks ago

Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference

REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...
By GlobeNewswire Inc. - 10 weeks ago

Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...
By GlobeNewswire Inc. - 11 weeks ago

Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...
By GlobeNewswire Inc. - 11 weeks ago